tm logo
NANT CANCER VACCINE
Live/Registered
REGISTERED

on 03 Sep 2024

Last Applicant/ Owned by

9920 Jefferson Blvd.

Culver City

CA

92032

Serial Number

97599709 filed on 20th Sep 2022

Registration Number

7491160 registered on 03rd Sep 2024

in the Principal Register

Correspondent Address

Michael J. McCue

Michael J. McCue LEWIS ROCA ROTHGERBER CHRISTIE LLP

LAS VEGAS, NV 89169

UNITED STATES

Filing Basis

1. filed as use application

2. use application currently

Disclaimer

NO DATA

NANT CANCER VACCINE

pharmaceutical preparations and substances for the treatment of human diseases in the nature of non-cancerous neoplasia, immunologic-related diseases, and immunologic dysfunction, animal diseases, autoimmune diseases, infectious diseases and cancer for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations and substances for the prevention, diagnosis, an Read More

Classification Information


Class [005]
Pharmaceutical Products


pharmaceutical preparations and substances for the treatment of human diseases in the nature of non-cancerous neoplasia, immunologic-related diseases, and immunologic dysfunction, animal diseases, autoimmune diseases, infectious diseases and cancer for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations and substances for the prevention, diagnosis, and treatment of human diseases in the nature of non-cancerous neoplasia, immunologic-related diseases, and immunologic dysfunction, animal diseases, autoimmune diseases, infectious diseases and cancer; pharmaceutical and biological preparations for use in targeted immunotherapy for the treatment of human diseases in the nature of non-cancerous neoplasia, immunologic-related diseases, and immunologic dysfunction, animal diseases, autoimmune diseases, infectious diseases and cancer; biological preparations for medical purposes, namely, vaccine preparations; low-dose chemotherapeutics, low dose radiopharmaceutical preparations, and personalized neoepitope-targeted pharmaceutical preparations for medical use for the treatment of human diseases in the nature of non-cancerous neoplasia, immunologic-related diseases, and immunologic dysfunction, animal diseases, autoimmune diseases, infectious diseases, and cancer; anti-cancer preparations; vaccines; biological preparations, namely, cell-derived preparations, cell therapeutics, monoclonal antibodies, cytokines, immune modulators, low-dose chemotherapeutics, low-dose radiation therapeutics, antibodies, fusion proteins, peptide and cytokine biological preparations, vaccines, personalized neoepitope-based therapeutics, and natural killer cell derived preparations, for the treatment of non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, autoimmune diseases, infectious diseases, animal diseases, and cancer for clinical, medicinal, therapeutic, and veterinary purposes; kits comprising cell cultures, reagents and related instructions, for use in the treatment and prevention of non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, autoimmune diseases, infectious diseases, animal diseases and cancer, for clinical, medicinal, therapeutic and veterinary purposes


First Use Date in General

19th Jul 2022

First Use Date in Commerce

19th Jul 2022

Mark Details


Serial Number

No 97599709

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 155500-00418

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
03rd Sep 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
03rd Sep 2024REGISTERED-PRINCIPAL REGISTER
18th Jun 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
18th Jun 2024PUBLISHED FOR OPPOSITION
29th May 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
14th May 2024APPROVED FOR PUB - PRINCIPAL REGISTER
14th May 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
14th May 2024EXAMINERS AMENDMENT E-MAILED
14th May 2024EXAMINER'S AMENDMENT ENTERED
14th May 2024EXAMINERS AMENDMENT -WRITTEN